JP2019506159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506159A5 JP2019506159A5 JP2018538551A JP2018538551A JP2019506159A5 JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5 JP 2018538551 A JP2018538551 A JP 2018538551A JP 2018538551 A JP2018538551 A JP 2018538551A JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- factor
- complement factor
- aptamer according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022039070A JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281092P | 2016-01-20 | 2016-01-20 | |
| US62/281,092 | 2016-01-20 | ||
| US201662297095P | 2016-02-18 | 2016-02-18 | |
| US62/297,095 | 2016-02-18 | ||
| PCT/US2017/014458 WO2017127761A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for inhibiting factor d |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Division JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Division JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506159A JP2019506159A (ja) | 2019-03-07 |
| JP2019506159A5 true JP2019506159A5 (https=) | 2020-02-27 |
Family
ID=59362699
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538551A Pending JP2019506159A (ja) | 2016-01-20 | 2017-01-20 | Ｄ因子を阻害するための組成物および方法 |
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10174325B2 (https=) |
| EP (1) | EP3405577B8 (https=) |
| JP (3) | JP2019506159A (https=) |
| CN (1) | CN108934169A (https=) |
| AU (3) | AU2017210042B2 (https=) |
| CA (1) | CA3011819A1 (https=) |
| GB (1) | GB2553252B (https=) |
| WO (1) | WO2017127761A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200182T1 (hr) | 2014-02-25 | 2020-05-01 | Achillion Pharmaceuticals, Inc. | Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) * | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018136831A1 (en) * | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
| KR20210104071A (ko) | 2018-12-17 | 2021-08-24 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 표적 투약 |
| WO2020146731A1 (en) * | 2019-01-11 | 2020-07-16 | Drive Therapeutics Llc | Compositions and methods for inhibiting vascular endothelial growth factor |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| EP4048318A4 (en) * | 2019-10-23 | 2023-11-22 | Gemini Therapeutics Sub, Inc. | METHOD FOR TREATING PATIENTS WITH CFH MUTATIONS USING RECOMBINANT CFH PROTEINS |
| CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
| WO2025080823A1 (en) * | 2023-10-11 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Treatment of macular degeneration with complement factor d (cfd) inhibitors |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US6653340B1 (en) | 1997-06-03 | 2003-11-25 | Biocryst Pharmaceuticals, Inc. | Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
| WO1999027133A1 (en) | 1997-11-26 | 1999-06-03 | Medical Research Council | Improved selex procedure and an anti-cd4 aptamer |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
| EP1594541A4 (en) | 2003-02-21 | 2007-03-28 | Rikshospitalet Radiumhospitale | METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME |
| ES2432112T3 (es) | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| AU2006223108A1 (en) | 2005-03-11 | 2006-09-21 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration |
| CA2610340C (en) | 2005-05-26 | 2016-02-16 | Vernon Michael Holers | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP2433642B1 (en) | 2005-10-21 | 2016-12-07 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| CN101346473A (zh) | 2005-12-22 | 2009-01-14 | 爱尔康研究有限公司 | 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂 |
| ATE466081T1 (de) | 2005-12-22 | 2010-05-15 | Opko Ophthalmics Llc | Zusammensetzungen und verfahren zur regulierung eines komplementsystems |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| KR101584468B1 (ko) | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| US8790924B2 (en) | 2006-10-19 | 2014-07-29 | Duke University | Reversible platelet inhibition |
| CN106188303A (zh) | 2006-11-02 | 2016-12-07 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
| US20080269318A1 (en) * | 2007-04-30 | 2008-10-30 | Carmelo Romano | Treatment of age-related macular degeneration using inhibitors of complement factor d |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| US8981060B2 (en) | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| GB0718737D0 (en) | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| UY31520A1 (es) | 2007-12-11 | 2009-08-03 | Proteinas de union a antigenos | |
| EP2254411A4 (en) | 2008-02-19 | 2012-06-13 | Univ Pennsylvania | COMPLEMENT INHIBITORS AS A THERAPEUTIC FOR THE TREATMENT OF CANCER |
| WO2009108931A2 (en) | 2008-02-28 | 2009-09-03 | Case Western Reserve University | Method of treating cancer |
| US8435512B2 (en) | 2008-03-03 | 2013-05-07 | Novelmed Therapeutics, Inc. | Anti-properdin antibodies |
| US8664362B2 (en) | 2008-03-03 | 2014-03-04 | NovelMed Therapeutics | Humanized and chimeric anti-properdin antibodies |
| EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| EP2159286A1 (en) | 2008-09-01 | 2010-03-03 | Consiglio Nazionale Delle Ricerche | Method for obtaining oligonucleotide aptamers and uses thereof |
| US20110160636A1 (en) | 2008-09-10 | 2011-06-30 | Rekha Bansal | Device and method for inhibiting complement activation |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| US9382544B2 (en) | 2009-05-15 | 2016-07-05 | Nec Solution Innovators, Ltd. | Aptamer that recognizes peptide |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| US9278108B2 (en) | 2009-07-16 | 2016-03-08 | Nec Solution Innovators, Ltd. | HMGB1 binding nucleic acid molecule and applications thereof |
| US20120190578A1 (en) | 2009-08-06 | 2012-07-26 | Washington University | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| DK2635704T3 (en) | 2010-11-01 | 2017-06-19 | Hoffmann La Roche | Predicting progression to advanced age-related macular degeneration using a polygenic score |
| EP2661433B1 (en) | 2011-01-04 | 2017-08-16 | Novartis AG | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| CN103796667A (zh) | 2011-06-22 | 2014-05-14 | 艾普莱斯制药公司 | 用补体抑制剂治疗慢性障碍的方法 |
| US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
| WO2013047844A1 (ja) | 2011-09-28 | 2013-04-04 | 株式会社リボミック | Ｎｇｆに対するアプタマー及びその用途 |
| EP2798085B1 (en) | 2011-12-30 | 2018-01-24 | Quest Diagnostics Investments Incorporated | Aptamers and diagnostic methods for detecting the egf receptor |
| MX374090B (es) | 2013-03-14 | 2025-03-05 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico. |
| AU2014306867B2 (en) | 2013-08-12 | 2017-10-26 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| HRP20200182T1 (hr) | 2014-02-25 | 2020-05-01 | Achillion Pharmaceuticals, Inc. | Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja |
| EP3137503A1 (en) * | 2014-05-01 | 2017-03-08 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
| TWI623617B (zh) | 2014-08-29 | 2018-05-11 | 國立清華大學 | 對卵巢癌具有專一性之適合體及其應用 |
| US20180356408A1 (en) | 2015-11-19 | 2018-12-13 | Base Pair Biotechnologies, Inc. | Methods and materials for sensitive detection of target molecules |
| WO2017127762A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Methods for improved aptamer selection |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018136831A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| WO2019022986A1 (en) | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
-
2017
- 2017-01-20 EP EP17742071.8A patent/EP3405577B8/en active Active
- 2017-01-20 AU AU2017210042A patent/AU2017210042B2/en active Active
- 2017-01-20 GB GB1718801.2A patent/GB2553252B/en active Active
- 2017-01-20 JP JP2018538551A patent/JP2019506159A/ja active Pending
- 2017-01-20 WO PCT/US2017/014458 patent/WO2017127761A1/en not_active Ceased
- 2017-01-20 CA CA3011819A patent/CA3011819A1/en active Pending
- 2017-01-20 CN CN201780018764.5A patent/CN108934169A/zh active Pending
- 2017-08-31 US US15/693,361 patent/US10174325B2/en active Active
-
2018
- 2018-09-04 US US16/121,458 patent/US20190161755A1/en not_active Abandoned
-
2020
- 2020-01-14 US US16/742,741 patent/US11274307B2/en active Active
-
2021
- 2021-04-20 AU AU2021202392A patent/AU2021202392B2/en active Active
-
2022
- 2022-03-14 JP JP2022039070A patent/JP2022078283A/ja active Pending
-
2023
- 2023-04-27 AU AU2023202548A patent/AU2023202548A1/en not_active Abandoned
- 2023-12-27 JP JP2023220791A patent/JP2024029136A/ja active Pending
-
2024
- 2024-07-05 US US18/765,089 patent/US20250197868A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506159A5 (https=) | ||
| JP2009531283A5 (https=) | ||
| CY1122476T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι) | |
| JP2011515073A5 (https=) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2008140653A3 (en) | Humaneered anti-factor b antibody | |
| MX2020000435A (es) | Anticuerpos anti-cd166 y usos de estos. | |
| UY28641A1 (es) | Anticuerpos | |
| PE20200757A1 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| AR046682A1 (es) | Terapia de combinacion para tratamiento de desordenes neovasculares oculares | |
| NZ600348A (en) | Anti-c5a binding moieties with high blocking activity | |
| DK1819830T3 (da) | Fremgangsmåder til antistofgenerering | |
| PL1772465T3 (pl) | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność | |
| RU2010138612A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR | |
| ES2675375T3 (es) | Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer | |
| JP2017113019A5 (https=) | ||
| EP1425042A4 (en) | COMPLEMENTARY PATIENT INHIBITORS BINDING AT C5 AND C5A WITHOUT PREVENTING THE FORMATION OF C5B | |
| JP2017507657A5 (https=) | ||
| NZ598770A (en) | Monoclonal antibodies | |
| JP2002505841A5 (https=) | ||
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| CN115768476A (zh) | 抗il-17a抗体药物组合物及其用途 | |
| WO2004075838A3 (en) | Method and compositions for the treatment of meconium aspiration syndrome | |
| WO2013177035A3 (en) | Humaneered anti-factor b antibody | |
| JP2022119899A5 (https=) |